2813-3935

Frontiers in Hematology

Frontiers Media SA

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 196 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact196 DOIs
2

Add abstracts to 10 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact10 DOIs
3

Deposit reference lists for 4 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact4 DOIs

DOIs for this ISSN

Showing the top 5 of 196 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 De novo drug design through artificial intelligence: an intr… (10.3389/frhem.2024.1305741)
ORCID
38.91 35
2 The impact of NETosis on hematological malignancies as a pro… (10.3389/frhem.2024.1377806)
Abstract ORCID
38.91 5
3 Sickle cell disease: a comparative perspective on global and… (10.3389/frhem.2024.1457158)
ORCID
34.51 23
4 Global burden and unmet needs in the treatment of transfusio… (10.3389/frhem.2023.1187681)
ORCID
33.56 21
5 Development of the sickle Pan-African research consortium re… (10.3389/frhem.2023.1040720)
ORCID
29.40 14
6 Research and clinical updates on IRAK4 and its roles in infl… (10.3389/frhem.2024.1339870)
ORCID
28.65 13
7 Benefits and limitations of humanized mouse models for human… (10.3389/frhem.2022.1062705)
ORCID
27.85 12
8 How artificial intelligence revolutionizes the world of mult… (10.3389/frhem.2024.1331109)
ORCID
27.85 12
9 Recent advancements in gene therapy for sickle cell disease… (10.3389/frhem.2024.1468952)
ORCID
27.85 12
10 Impact of haemoglobinopathies on asymptomatic Plasmodium fal… (10.3389/frhem.2023.1150134)
ORCID
26.98 11
11 Asymmetric cell division of hematopoietic stem cells: recent… (10.3389/frhem.2024.1373554)
ORCID
26.98 11
12 The nexus between Helicobacter pylori infection and anemia—a… (10.3389/frhem.2024.1423494)
ORCID
26.03 10
13 Recent progress in analyses of GATA1 in hematopoietic disord… (10.3389/frhem.2023.1181216)
ORCID
23.86 8
14 The link between immune thrombocytopenia and the cytokine pr… (10.3389/frhem.2023.1191178)
ORCID
23.86 8
15 Exploring extramedullary hematopoiesis: unraveling the hemat… (10.3389/frhem.2024.1371823)
ORCID
23.86 8
16 The aging hematopoietic stem cell niche: a mini review (10.3389/frhem.2025.1525132)
ORCID
23.86 8
17 The role of glucocorticoids in erythropoiesis (10.3389/frhem.2025.1540152)
ORCID
23.86 8
18 Red blood cells from patients with sitosterolemia exhibit im… (10.3389/frhem.2023.1055086)
ORCID
22.58 7
19 Are we ready to integrate 3D culture systems in acute myeloi… (10.3389/frhem.2024.1407698)
ORCID
22.58 7
20 Case Report: A case of IgD lambda/lambda Multiple Myeloma in… (10.3389/frhem.2022.974392)
ORCID
19.45 5
21 Case Report: Thrombopoietin receptor agonists in resistant t… (10.3389/frhem.2023.1180156)
ORCID
19.45 5
22 R-loops in normal and malignant hematopoiesis (10.3389/frhem.2023.1297657)
ORCID
19.45 5
23 Bcl-2 inhibition in the treatment of hematologic malignancie… (10.3389/frhem.2023.1307661)
ORCID
19.45 5
24 Blood pharming: exploring the progress and hurdles in produc… (10.3389/frhem.2024.1373408)
ORCID
19.45 5
25 Dissecting dormancy and quiescence in hematopoietic stem cel… (10.3389/frhem.2024.1401713)
ORCID
19.45 5
26 Targeting the bone marrow niche, moving towards leukemia era… (10.3389/frhem.2024.1429916)
ORCID
19.45 5
27 The CHIP-clinic as the catalyst of preventive medicine (10.3389/frhem.2024.1459154)
ORCID
19.45 5
28 HPLC first approach in detecting thalassemia and other commo… (10.3389/frhem.2025.1461498)
ORCID
19.45 5
29 Predicting outcomes of hematological malignancy patients adm… (10.3389/frhem.2023.1127322)
ORCID
17.47 4
30 Mini review: Advances and challenges in CAR-T cell therapy:… (10.3389/frhem.2023.1217775)
ORCID
17.47 4
31 Case report: Childhood erythrocytosis due to hypermanganesem… (10.3389/frhem.2024.1331485)
ORCID
17.47 4
32 Predicting factors of survival rates among alpha- and beta-t… (10.3389/frhem.2024.1339026)
ORCID
17.47 4
33 Crizanlizumab in adult patients with sickle cell disease: a… (10.3389/frhem.2024.1374181)
ORCID
17.47 4
34 Clonal cytopenia of undetermined significance: definitions,… (10.3389/frhem.2024.1419323)
ORCID
17.47 4
35 Case report: Vitamin B12 deficiency-associated hemolytic ane… (10.3389/frhem.2024.1446241)
ORCID
17.47 4
36 Case report: VEXAS syndrome and literature review (10.3389/frhem.2024.1480436)
ORCID
17.47 4
37 Impact of leukemia subtype and demographics on patient quali… (10.3389/frhem.2024.1502166)
ORCID
17.47 4
38 Ex vivo culture of malignant primary B cells (10.3389/frhem.2022.1004717)
ORCID
15.05 3
39 Ropeginterferon-alfa2b resolves angina pectoris and reduces… (10.3389/frhem.2022.1005666)
ORCID
15.05 3
40 Impact of insurance status and distance from residence to tr… (10.3389/frhem.2022.1060029)
ORCID
15.05 3
41 A systematic review investigating advances in gene therapy f… (10.3389/frhem.2023.1216596)
ORCID
15.05 3
42 Nivolumab and daratumumab combination regimens for the treat… (10.3389/frhem.2023.1244494)
ORCID
15.05 3
43 Case report: A patient with ALK-positive large B-cell lympho… (10.3389/frhem.2024.1334577)
ORCID
15.05 3
44 Exploring the intricate cross-talk between clonal expansion… (10.3389/frhem.2024.1334807)
ORCID
15.05 3
45 Hypersialylation and multiple myeloma (10.3389/frhem.2024.1360149)
ORCID
15.05 3
46 Early T-cell precursor acute lymphoblastic leukemia: diagnos… (10.3389/frhem.2024.1463410)
ORCID
15.05 3
47 Delineation of erythropoietic intermediates by flow cytometr… (10.3389/frhem.2024.1496916)
ORCID
15.05 3
48 Case Report: Teclistamab in the treatment of idiopathic immu… (10.3389/frhem.2025.1547209)
Abstract ORCID
15.05 1
49 Trends in hemolytic anemia-related mortality in the United S… (10.3389/frhem.2025.1560766)
ORCID
15.05 3
50 Metabolic reprogramming of fetal hematopoietic stem and prog… (10.3389/frhem.2025.1575143)
ORCID
15.05 3